We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 13, 2020

Docetaxel Improves Survival in Metastatic Hormone-Naïve Prostate Cancer

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Addition of Docetaxel to Hormonal Therapy in Low- and High-Burden Metastatic Hormone Sensitive Prostate Cancer: Long-Term Survival Results From the STAMPEDE Trial
Ann. Oncol 2019 Sep 27;[EPub Ahead of Print], NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, J Calvert, S Chowdhury, A Cook, W Cross, DP Dearnaley, H Douis, D Gilbert, S Gillessen, RJ Jones, RE Langley, A MacNair, Z Malik, MD Mason, D Matheson, R Millman, CC Parker, AWS Ritchie, H Rush, JM Russell, J Brown, S Beesley, A Birtle, L Capaldi, J Gale, S Gibbs, A Lydon, A Nikapota, A Omlin, JM O'Sullivan, O Parikh, A Protheroe, S Rudman, NN Srihari, M Simms, JS Tanguay, S Tolan, J Wagstaff, J Wallace, J Wylie, A Zarkar, MR Sydes, MKB Parmar, ND James

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading